ILMN

$124.33-2.26 (-1.79%)

Market ClosedAs of Mar 20, 8:00 PM UTC

Illumina, Inc.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$124.33
Potential Upside
19.4%
Whystock Fair Value$148.42
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDiagnostics & Research

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consu...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$19.01B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
22.81
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.50
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
46.16%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.72

Recent News

Zacks
Mar 19, 2026

ILMN Stock Gains Following Expanded Collaboration With Labcorp

Illumina gains after expanding Labcorp collaboration to boost NGS oncology adoption, broaden testing access, and drive growth in precision cancer care.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 19, 2026

How The Illumina (ILMN) Story Is Shifting With 2026 Expectations And Mixed Street Views

Illumina’s fair value estimate has been adjusted slightly, moving from US$135.94 to US$136.05, signaling only a very modest change in the modeled price target. That small shift sits against a backdrop of mixed analyst views, with some research teams lifting targets on the back of what they describe as improving end markets into 2026, while others worry that recent share moves already price in a stronger Q4 and 2026 setup. As you read on, you will see how these updates fit into the broader...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 18, 2026

Life Sciences Tools & Services Stocks Q4 Earnings: Illumina (NASDAQ:ILMN) Firing on All Cylinders

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Illumina (NASDAQ:ILMN) and its peers.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Investor's Business Daily
Mar 16, 2026

Illumina Stock Sees RS Rating Jump To 82

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Illumina stock cleared that benchmark Monday, with a jump from 77 to 82 Monday.   Hone Your Stock-Picking Skills By Focusing On These Factors This unique rating measures market leadership by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 15, 2026

Assessing Illumina (ILMN) Valuation After Expanded Genomics And Proteomics Alliance With Regeneron

Illumina (ILMN) is back in focus after expanding its Alliance for Genomic Discovery with Regeneron Genetics Center and launching a dataset of more than 50,000 genomes plus proteomic data using Illumina Protein Prep, targeting multiomic drug discovery research. See our latest analysis for Illumina. Despite the latest alliance news, Illumina’s share price at US$118.94 reflects mixed momentum, with a 2.92% 1 day share price return but a 90 day share price return decline of 11.84%. The 1 year...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.